NOVEL ANTIBODIES INHIBITING c-MET DIMERIZATION, AND USES THEREOF

Japanese Patent JP2014113154

A

To provide an antibody capable of inhibiting a dimerization of c-Met and its partner as well as of binding to c-Met as a medicament for prevention or therapeutic treatment of a cancer involving overexpression of human c-Met receptor or any condition of the diseases.

The anti c-Met antibody consists of a heavy chain comprising CDR-H1, CDR-H2, and CDR-H3 and a light chain comprising CDR-L1, CDR-L2, and CDR-L3, and the anti c-Met antibody or functional divalent fragment thereof has a specific amino acid sequence. A pharmaceutical composition comprises the antibody for producing a medicament for treating cancer. Or a diagnostic process and a kit comprising the antibody. The pharmaceutical composition comprises an antibody derived from mouse, chimera, or human, or a monoclonal antibody.

WO/2010/143435	VACCINE THERAPY FOR CHOROIDAL NEOVASCULARIZATION
JPH06509712	INDUSTRIAL APPLICABILITY: A device for detecting impurities in water.
WO/2003/090515	SYSTEMS AND METHODS FOR DETECTION OF NUCLEAR RECEPTOR FUNCTION USING REPORTER ENZYME MUTANT COMPLEMENTATION

GOETSCH LILIANE

JP2014000617A

June 26, 2014

January 06, 2014

Click for automatic bibliography generation  

PF MEDICAMENT

C12N15/09; A01K67/027; A61K39/395; A61K45/00; A61P35/00; C07K16/30; C07K16/32; C07K16/46; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/02; C12P21/02; C12P21/08; G01N33/53; G01N33/532

US20050233960A1	2005-10-20
WO2006015371A2	2006-02-09
US6207152B1	2001-03-27
US20050233960A1	2005-10-20
WO2006015371A2	2006-02-09
US6207152B1	2001-03-27

JPN6013031894; Ｃａｎｃｅｒ　Ｒｅｓ． Ｖｏｌ．６６，　Ｎｏ．３, 20060201, ｐ．１７２１-１７２９
JPN6013031894; Ｃａｎｃｅｒ　Ｒｅｓ． Ｖｏｌ．６６，　Ｎｏ．３, 20060201, ｐ．１７２１-１７２９

Hirohito Katsunuma
Yukitaka Nakamura
Noritaka Yokota
Omori Miko

Previous Patent: NOVEL ANTIBODIES INHIBITING c-MET DIMERIZATION, AND USES THEREOF

Next Patent: NEW ANTIBODY INHIBITING DIMERIZATION OF c-MET AND USE THEREOF